Saratov JOURNAL of Medical and Scientific Research

The vitreoretinal interface pathology and anti-VEGF therapy of macular edema in diabetic angioretinopathy

Year: 2020, volume 16 Issue: №2 Pages: 635-638
Heading: Ophtalmology Article type: Original article
Authors: Oskanov D.H., Sosnovskii S.V., Boiko E.V.
Organization: S. Fyodorov Eye Microsurgery Federal State Institution

The purpose of the study is to assess the effect of vitreoretinal interface changes in patients with diabetic macular edema as far as the effectiveness of anti-VEGF therapy is concerned. Material and Methods. The study included 198 patients (198 eyes) with diabetic macular edema (DME). Two groups were formed: group 1 — patients without pathological changes in vitreoretinal interface (VRI); group 2 — patients with pathological changes in VRI. We studied the best-corrected visual acuity according to the Snellen table, central retinal thickness and VRI condition according to optical coherence tomography before the intravitreal administration and 1 month after. Results. Significant differences in best-corrected visual acuity were observed before and 1 month after intravitreal administration in both groups (p<0.05). A significant decrease in central retinal thickness in both groups was revealed (p<0.001). A statistically significantly larger average decrease in the thickness of the central retinal in group 1 was obtained (p<0.001). Conclusion. Improvement in visual acuity is significant in anti-VEGF therapy of DME with normal VRI, while with the pathological VRI it is not significant. The degree of improvement in average visual acuity and the degree of decrease in the average thickness of the central retina during anti-VEGF therapy of DME is significantly lower in the presence of VRI pathology. Presence of the vitreoretinal interface pathology reduces the effectiveness of antiangiogenic therapy of DME.

1. Musat О, Cernat С, Labib M, et al. Diabetic macular edema. Romanian J Ophthalmol 2015; 59 (3): 133-6.
2. Нее MR, Izatt JA, Swanson EA, et al. Optical coherence tomography of the human retina. Arch Ophthalmol 1995; 113 (3): 325-32.
3. Neroev VV. Current issues in the treatment of diabetic macular edema. Russian Ophthalmological Journal 2012; 5 (1): 4-7.
4. Kulikov AN, Sosnovskii SV, Berezin RD, et al. Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study. Clin Ophthalmol 2017; 11: 1995-2002. DOI: 10.2147/OPTH. S146019. eCollection 2017.
5. Kulikov AN, Sosnovskii SV, Berezin RD, et al. Dynamics of vitreomacular interface pathology in patients with DMO on the background of antiVEGF therapy. In: VII All-Russian (with foreign participation) seminar «MAKULA-2016». Rostov-on-Don, 2016; p. 206-17.
6. Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-Week Results from the VISTA and VIVID Studies. Ophthalmology 2015; 122 (10): 2044-52. DOI: 10.1016/j. ophtha. 2015.06.017.
7. Boiko EV, Sosnovskii SV, Berezin RD, etal. Antiangiogenic therapy in ophthalmology. St. Petersburg: Military Medical Academy n. a. S.M. Kirov, 2013; 292 p.
8. Maier М, Abraham S, Frank С, et al. Therapeutic Options in Vitreomacular Traction with or without a Macular Hole. Klin Monbl Augenheilkd 2016; 233 (5): 622-30.
9. Kozak I, Barteselli G, Sepah YJ, et al. Correlation of Vitreomacular Traction with Foveal Thickness, Subfoveal Choroidal Thickness, and Vitreomacular/Foveal Angle. Curr Eye Res 2017; 42 (2): 297-301.

2020_02-1_635-638.pdf505.15 KB

No votes yet